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Abstract
As survival of acute lymphoblastic leukemia (ALL) exceeds 90%, limiting therapy-related
toxicity has become a key challenge. Cardio-metabolic dysfunction is a challenge during
and after childhood ALL therapy. In a single center study, we measured triglycerides (TG),
total cholesterol (TC), high (HDL) and low density lipoproteins (LDL) levels at diagnosis and
assessed the association with BMI, early therapy response, on-therapy hyperlipidemia and
the toxicities; thromboembolism, osteonecrosis and pancreatitis. We included 127 children
(1.0–17.9 years) all treated according to the NOPHO ALL2008 protocol. Dyslipidemia was
identified at ALL-diagnosis in 99% of the patients, dominated by reduced HDL levels (98%)
and mild hypertriglyceridemia (61%). Hypertriglyceridemia was not associated with body
mass index (P = 0.71). Five percent of patients had mild hypercholesterolemia, 14% had
mild hypocholesterolemia, 13% had decreased and 1% elevated LDL-levels. Increased TG
and TC levels at ALL-diagnosis were not associated with any on-therapy lipid levels. Lipid
levels and BMI were not associated to MRD after induction therapy; However, BMI and
hypercholesterolemia were associated with worse risk group stratification (P<0.045 for all).
The cumulative incidence of thromboembolism was increased both for patients with hypo-
(20.0%) and hypercholesterolemia (16.7%) compared to patients with normal TC levels
(2.2%) at diagnosis (P = 0.0074). In conclusion, dyslipidemic changes were present prior to
ALL-therapy in children with ALL but did not seem to affect dysmetabolic traits during ther-
apy and were not predictive of on-therapy toxicities apart from an association between dys-
cholesterolemia at time of ALL-diagnosis and risk of thromboembolism. However, the latter
should be interpreted with caution due to low number in the groups.
Introduction
Intensification of therapy has yielded survival rates above 90 percent in children with acute
lymphoblastic leukemia (ALL)[1]. However, this intensification has led to severe therapy-
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related toxicity as well. Thus, more than 50% of children diagnosed with ALL experience toxic-
ity during or after therapy [2,3]. While mechanisms between anti-leukemic drugs and toxicity
have been well-studied, studies on potential predictive risk factors prior to ALL therapy have
been limited. Identification of such risk modifiers could enable interventions and decrease
acute and chronic toxicities in children with ALL.
Obesity and metabolic dysfunction play a major role in survivors of childhood ALL leading
to increased risk of morbidity and mortality throughout their life[3–6]. Altered lipid metabo-
lism caused by intensive therapy has been addressed [7–11] and contradictory associations to
toxicities such as thromboembolism[12–15], osteonecrosis[16,17] and pancreatitis[18–24]
have been reported. Furthermore, abnormal lipid levels prior to ALL therapy[25–29] and obe-
sity at time of ALL-diagnosis have been associated with reduced efficacy of induction therapy,
impaired event-free and overall survival[30–32] as well as suggested as a part of the leukomo-
genisis[33]. However, the mechanism of an altered lipid metabolism in childhood ALL has yet
to be elucidated.
Accordingly, the aim of this retrospective study was to explore lipid profiles in children
diagnosed with ALL prior to onset of therapy, and its potential association with BMI, early
therapy response, on-therapy hyperlipidemia and/or steroid- and asparaginase-associated tox-
icities; thromboembolism, osteonecrosis and pancreatitis.
Methods
Patient population
All children (1 to 17.9 years of age) diagnosed with Philadelphia chromosome negative B-cell
precursor or T-lineage ALL from July 2008 to December 2016 at Copenhagen University Hos-
pital Rigshospitalet (Denmark) and enrolled in the Nordic Society of Pediatric Hematology
Oncology 2008 (NOPHO ALL2008) protocol were included in the study. Patients with Down
syndrome or who received glucocorticoid treatment prior to ALL-diagnosis were excluded
from the study cohort.
NOPHO ALL2008 protocol
The NOPHO ALL2008 protocol is described in detail elsewhere[34]. In brief, patients were
stratified into high risk (HR) or non-HR treatment groups at time of diagnosis based on white
blood cell count (WBC) and immunophenotype. Following induction (day 29) and consolida-
tion (day 79) patients were subsequently stratified into three risk groups; standard risk (SR),
intermediate risk (IR), and HR based on cytogenetics as well as treatment response measured
through levels of minimal residual disease (MRD). Induction therapy consisted of a systemic
three-drug regimen including Vincristine and Doxorubicine and either Prednisolone or Dexa-
methasone for non-HR and HR, respectively. Additionally, intrathecal methotrexate or triple
therapy was administered depending on CNS involvement (triple for CNS 2/3). Pegylated
asparaginase, 6-mercaptopurine and high-dose methotrexate therapy were given from early
consolidation phase.
All patients included in the protocol were prospectively registered regarding demographics,
anthropometric measurements, and disease characteristics (immunophenotype, WBC, medias-
tinal mass, MRD, risk group at diagnosis/day 29/day 79, treatment-related toxicities, relapse,
secondary malignancy and death). We retrieved data on thromboembolism, osteonecrosis and
pancreatitis. Each toxicity was identified based on the Ponte di Legno criteria (PdL)[2]. Venous
and/or arterial thromboembolism was registered if confirmed by imaging (ultrasound, CT, or
MRI) or by autopsy[2]. Osteonecrosis was indicated by pain in at least one joint, limited activi-
ties of daily living and confirmed by MRI [2]. Pancreatitis was registered if at least two of three
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features were fulfilled: abdominal pain suggestive of pancreatitis; serum lipase or amylase three
or more times above upper normal limit (UNL); and characteristic image findings suggestive of
pancreatitis (ultrasound, CT, or MRI)[2].
Blood samples at time of ALL-diagnosis
Blood samples were systematically collected at time of diagnosis before onset of induction
therapy prior to or during anesthesia. Patients were fasting at the time point when the blood
sample was taken; allowing clear liquids up to two hours and solid foods up to six hours prior
to the onset of anesthesia. The lipid analysis (TG, TC, LDL, HDL) were either performed the
same day or stored in minus 80 degrees Celsius until batch analysis.
Standardized measurements (WBC, hemoglobin levels, platelet levels, liver biomarkers etc.)
were collected before onset of therapy and were extracted from the NOPHO register and medi-
cal charts.
Lipid profiling
The lipid levels were categorized according to the normal limits (lower normal limit [LNL] =
2.5 percentile and UNL = 97.5 percentile) in sex and age matched healthy references defined
by an expert panel on integrated guidelines in the Danish Society of Clinical Biocehmistry[35–
37] (S1 Table). Dyslipidemia was defined as levels above or below the normal range in one or
more of the lipids. Hypertriglyceridemia and hypercholesterolemia, were defined and graded
according to the PdL consensus criteria based on triglycerides/cholesterol blood concentra-
tions: mild hypertriglyceridemia/hypercholesterolemia 1–10×UNL, moderate hypertriglyceri-
demia/hypercholesterolemia 10–20×UNL, severe hypertriglyceridemia/hypercholesterolemia
above 20×UNL[2]. Moreover, we defined the lipid levels as normal if within LNL and UNL
and decreased if below LNL.
On-therapy lipid levels
Lipid levels during therapy, including triglyceride and cholesterol levels, were collected from
electronic medical charts. Lipids during therapy were not measured systematically. If more
than one measurement was available from the same day, the mean of these measurements
were calculated.
Statistics
Age at diagnosis was divided into two groups; children aged 1 to 9.9 years and adolescents 10
to 17.9 years[38]. Body mass index (BMI) was calculated as weight in kilograms divided by
height in meters squared and converted to z-scores according to Danish references based on
the LMS method[39]. BMI z-scores at diagnosis were divided in three BMI groups defined as:
lean body weight <90th percentile, overweight 90th–99th percentile, and obesity�99th percen-
tile[39]. Triglyceride and cholesterol standard deviation (SD) scores were calculated based on
log-transformed values because especially triglycerides are right-skewed. The mean values and
SDs for log-triglycerides and log-cholesterol were calculated from the 2.5 and 97.5 percentiles
from the distribution of the healthy references assuming that these log-transformed would be
approximately normal. As for the BMI z-scores, the triglyceride and cholesterol SD scores
reflect how much a (log-) measurement deviates from the average of an age- and sex-matched
healthy reference group.
Associations between hypertriglyceridemia/hyper- and hypocholesterolemia/decreased
LDL and categorical and continuous characteristics at time of ALL-diagnosis, day 29, or day
PLOS ONE Dyslipidemia and childhood ALL
PLOS ONE | https://doi.org/10.1371/journal.pone.0231209 April 6, 2020 3 / 17
79 after diagnosis were analyzed by Fisher’s exact test and Wilcoxon two-sample rank sum
test, respectively. Correlations between lipid measurements at diagnosis were evaluated by
Spearman’s correlation coefficient.
To illustrate the data, on-therapy mean TG and mean TC were estimated with a cubic
smoothing spline with the smoothing parameter chosen by the leave-one-subject-out cross-
validation procedure. Subject uniform weights were used in the estimation assigning each
patient a weight depending on the patient’s number of repeated measurements. Approximate
95% percentile bootstrap pointwise confidence intervals for the estimated mean curves were
obtained from 1000 resampling-subject bootstrap samples. Mean curves were fitted separately
for patients with normal/hypertriglyceridemia and normal/hypocholesterolemia (hypercholes-
terolemia excluded because of too few patients) at time of ALL-diagnosis, respectively, and
both TG and TC were log2-transformed.
The 2.5-year cumulative incidences of thromboembolism, osteonecrosis, and pancreatitis
were estimated by the Aalen-Johansen estimator considering relapse, secondary malignancy,
and death as competing events, and the estimates were compared with Gray’s test. The Cox
proportional hazards model was used to calculate age-adjusted hazard ratios of thromboembo-
lism, osteonecrosis, and pancreatitis for the lipid levels at diagnosis with the significance evalu-
ated by Wald tests.
In all analyses two-sided P-values<0.05 were considered statistically significant. All analy-
ses were carried out using the statistical software SAS1 version 9.4[40] and R1 version 3.5.0
[41].
Ethics
The study has been approved by the ethical institutional review board of The Capital Region of
Denmark (Protocol no.: H-2-2010-002).
Results
A total of 127 children diagnosed with ALL (60% males) with a median age of 4.7 years of age
(interquartile range [IQR] 2.9–10.4) fulfilled the inclusion criteria. Information on demo-
graphic and disease specific characteristics is presented in Tables 1 and S2. Lipid levels mea-
sured at diagnosis were available for 112 patients (88.2%). The 15 patients without available
lipid measures did not differ from the included cohort in demographic and disease characteris-
tics. Of the 112 included patients, 82 patients had at least one on-therapy TG measurement
and 71 had at least one on-therapy TC measurement.
Lipid levels and BMI at time of ALL-diagnosis
The associations between TG and cholesterol levels at diagnosis are shown in Fig 1A–1C. The
inverse correlations between TG and HDL as well as TG and LDL were significant (p<0.0001
and p = 0.0069, respectively), while no correlation between TG and TC was found (p = 0.96).
Dyslipidemia was identified at time of ALL-diagnosis in 99% (111/112) of patients who had
lipid measures at time of ALL-diagnosis (Fig 2). We identified 66% (74/112) of patients with
combined dyslipidemia at time of ALL-diagnosis, primarily mild hypertriglyceridemia com-
bined with decreased HDL levels (47/112). HDL levels were reduced in 98% (110/112) and
normal in 2% (2/112) and mild hypertriglyceridemia were present in 58% (65/112) of the
patients at time of ALL-diagnosis. Mild hypercholesterolemia was present in 5% (6/112),
whereof three (3/112) also had hypertriglyceridemia. No patients had moderate or severe
hypertriglyceridemia or hypercholesterolemia at time of ALL-diagnosis. Conversely, 14% (15/
112) had mild hypocholesterolemia at time of ALL-diagnosis. LDL-levels were normal in 86%
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of the patients (96/112), and 13% (15/112) had decreased and 1% (1/112) elevated LDL-levels.
The combinations of altered lipid levels for the patients are illustrated in Fig 2, and characteris-
tics for patients and TG and TC levels at time of ALL-diagnosis are presented in Table 1, and
for LDL and BMI levels in S2 Table. BMI in the study cohort did not differ from healthy sex-
and age- matched references (median BMI z-score -0.03 [IQR -0.98−0.82]). No associations
Fig 1. Triglyceride levels and A) total cholesterol levels, B) high-density lipoprotein (HDL) levels, and C) low-density
lipoprotein (LDL) levels at time of ALL-diagnosis for 112 patients.
https://doi.org/10.1371/journal.pone.0231209.g001
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were found between mild hypertriglyceridemia/hypercholesterolemia and BMI groups
(P = 0.71 and P = 0.68, respectively) at time of diagnosis.
Patients with mild hypertriglyceridemia at time of ALL-diagnosis were significantly youn-
ger than patients with normal TG levels (median age 4.2 years [IQR 2.8–7.5] vs. 6.1 years [3.1–
12.0], P = 0.043), and the association was also significant when comparing children and adoles-
cents (<10 years vs.�10 years, P = 0.045). Contrary, patients with hypocholesterolemia were
older than patients with normal TC levels (P = 0.0017) (Table 1).
Immunophenotype and WBC was not associated with mild hypertriglyceridemia (P>0.99
and P = 0.56, respectively) (Table 1). Mediastinal mass was present in six patients with mild
hypertriglyceridemia vs. one patient without hypertriglyceridemia, all seven patients were
diagnosed with T-lineage leukemia (P = 0.12 and P = 0.24 for patients with T-lineage ALL and
for all patients, respectively). Ferritin levels and sedimentation reaction (SR) were significantly
lower in patients with hypertriglyceridemia compared to those with normal TG levels (ferritin
median 257 [IQR 178–362] vs. 394 [275–560]; and SR median 51 [IQR 24–80] vs. 74 [42–107])
and no difference were shown for C-reactive protein (CRP) (P = 0.58).
Six patients were present with mild hypercholesterolemia at time of ALL-diagnosis
(Table 1). Compared to patients with normal levels of TC, they were characterized by all being
males (P = 0.035), five/six had T lineage ALL (P = 0.00017) and thus stratified into HR at time
of ALL-diagnosis (P = 0.0026) and six/six stratified into either IR or HR at end of induction
and at day 79 (P = 0.024 and P = 0.029, respectively). Furthermore, hypercholesterolemia
tended to be associated with tumor burden since four/six had mediastinal mass at time of
ALL-diagnosis (P = 0.061) and three of six had WBC count above 50 ×109/L (P = 0.069).
Hypercholesterolemia was not statistically associated to BMI group; however, all six patients
Fig 2. Number of patients with (non)-combined dyslipidemia at time of ALL-diagnosis. One patient did not have dyslipidemia at diagnosis.
https://doi.org/10.1371/journal.pone.0231209.g002
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were lean at time of ALL-diagnosis. Patients with hypocholesterolemia at time of ALL-diagno-
sis did not differ in characteristics from patients with normal TC levels besides being older
(P = 0.0017) and having higher levels of ferritin and bilirubin at time of ALL-diagnosis
(P = 0.031 and P = 0.0081, respectively).
Early treatment response
MRD measures were missing for five patients at the end of induction (EOI) and additional 14
patients at day 79 (Table 1). Patients missing MRD at EOI or day 79 were either stratified into HR
already at day 15/29 due to poor response or died during therapy (one patient died during induc-
tion and two patients died during remission before day 79. No association was found between
lipid levels or BMI at time of ALL-diagnosis and MRD measures at end of induction and/or at
day 79. Using risk stratification at the end of induction and at day 79 as a proxy for risk of therapy
outcome we found a significant association between hypercholesterolemia at time of ALL-diagno-
sis and a poorer risk stratification at end of induction and day 79 (P = 0.024 and P = 0.025, respec-
tively). Likewise, overweight/obesity at time of ALL-diagnosis was associated with poorer risk
group stratification both after induction (P = 0.049) and at day 79 (P = 0.017) (S2 Table). Hyper-
triglyceridemia at time of ALL-diagnosis was not associated to risk group stratification at end of
induction (P = 0.24) though a tendency were seen at day 79 (P = 0.098) (Table 1).
On-therapy hypertriglyceridemia and hypercholesterolemia
Of the 112 patients with lipid measurements at time of ALL-diagnosis 82 patients had 1–98
(median 21, total 2070) on-therapy TG measurements, and of these 71 patients had 1–92
(median 23, total 1752) on-therapy TC measurements, reflecting that the sampling of on-ther-
apy lipids was highly irregular. The sampling frequency varied from 1–548 (median 4, IQR
1–8) days between on-therapy TG measurements from the same patient. Most of the lipid
measurements were from the first 270 days of therapy (during induction and asparaginase
therapy) (91.5% of the TG and 92.5% of the TC measurements).
On-therapy TG and total TC levels within the first 270 days of therapy are demonstrated
according to levels at time of ALL-diagnosis in Fig 3 for 80 patients with a median of 20 TG
measurements (IQR 11–32) and 65 patients (3 patients with hypertriglyceridemia excluded)
with median 23 TC measurements (IQR 14–32), respectively. We could not detect a difference
in development in TG or TC over time for the groups defined by at-diagnosis lipid levels illus-
trated by fitted curves with overlapping confidence intervals in Fig 3. The curve for hypercho-
lesterolemia could not be illustrated due to low numbers.
Neither was a difference identified when comparing the fitted curves for TG and TC on-
therapy levels for induction therapy groups (prednisolone [non-HR] vs. dexamethasone [HR],
respectively) (S1 Fig).
To illustrate the individual variation in TG on therapy, S2 and S3 Figs show the on-therapy
TG SD scores and raw measurements, respectively, for the 16 patients with most measure-
ments within the first year of therapy. S4 and S5 Figs similarly show the on-therapy TC SD
scores and raw measurements for the same 16 patients.
Toxicities
The cumulative incidences of thromboembolism, osteonecrosis, and pancreatitis were 5.5%
(95% CI 2.4–10.5), 7.2% (3.5–12.7), and 18.2% (12.1–25.4), respectively, and were not associ-
ated with age group in the study cohort (P>0.26 for all) (Table 2). The cumulative incidence of
any toxicity was 31.1% (22.9–39.4) with no significant association with age group or any of the
lipid levels at diagnosis (P>0.11 for all). The cumulative incidence of thromboembolism was
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significantly higher for patients with hypocholesterolemia (20.0%) and hypercholesterolemia
(16.7%) at diagnosis compared to patients with normal TC levels (2.2%) (P = 0.0074). Corre-
spondingly, the age-adjusted hazard ratio of thromboembolism was significantly associated
with dyscholesterolemia (9.3, 95% CI 1.7–50.8, P = 0.011) (S3 Table).
Fig 3. On-therapy levels of A) triglycerides with mean curves according to normal and mild hypertriglyceridemia at
time of ALL-diagnosis, and B) total cholesterol according to normal and hypocholesterolemia at time of ALL-
diagnosis. The shaded areas show the approximate 95% percentile bootstrap pointwise confidence intervals for the
estimated mean curves.
https://doi.org/10.1371/journal.pone.0231209.g003
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No other significant associations were found between the lipid levels or BMI level at time of
ALL-diagnosis and age-adjusted hazard rate of thromboembolism (P>0.78) (S3 Table), and
no significant associations with osteonecrosis or pancreatitis (P>0.25) (S3 Table).
Discussion
Tumor development influences the host lipid metabolism in animals by inducing hyperlipid-
emia partly through reprogramming of hepatic lipoprotein homeostasis[42]. This provides
enhanced cholesterol uptake by the tumor and supports its growth[42]. Metabolic dysfunction
Table 2. Cumulative incidences of toxicity.
Thromboembolism Osteonecrosis Pancreatitis
Total
cohort
N (%)
2.5-year
cumulative
incidence, %
(95% CI)
P-
value
2.5-year
cumulative
incidence, %
(95% CI)
P-
value
2.5-year
cumulative
incidence, %
(95% CI)
P-
value
Total 127 5.5 (2.4–10.5) 7.2 (3.5–12.7) 18.2 (12.1–25.4)
Age groups 0.26 0.55 0.32
Children, Age <10 years 95 (75) 4.2 (1.4–9.7) 6.4 (2.6–12.6) 20.1 (12.7–28.7)
Adolescents, Age�10
years
32 (25) 9.4 (2.3–22.5) 9.8 (2.4–23.6) 12.5 (3.9–26.5)
Triglyceride levels at time
of ALL-diagnosis
0.67 0.63 0.32
Normal (<UNL) 47 (42) 6.4 (1.6–15.9) 8.6 (2.7–18.9) 12.8 (5.1–24.0)
Mild hypertriglyceridemia
(�UNL and <10xUNL)
65 (58) 4.6 (1.2–11.8) 6.3 (2.0–14.2) 20.0 (11.3–30.5)
Total cholesterol levels at
time of ALL-diagnosis
0.0074 0.49 0.52
Hypocholesterolemia
(<LNL)
15 (14) 20.0 (4.5–
43.3)
13.3 (2.0–35.4) 20.0 (4.5–43.3)
Normal 91 (81) 2.2 (0.004–
6.9)
6.7 (2.7–13.3) 17.6 (10.6–26.1)
Mild hypercholesterolemia
(�UNL and <10xUNL)
6 (5) 16.7 (4.8–
54.9)
- -
LDL levels at time of ALL-
diagnosis
0.94 0.59 0.48
Decreased (<LNL) 15 (13) 6.7 (0.4–26.9) 13.3 (2.0–35.5) 26.7 (7.7–50.5)
Normal 96 (86) 5.2 (1.49–11) 6.4 (2.6–12.7) 15.6 (9.2–23.6)
Increased (�UNL) 1 (1) - - -
HDL levels at time of
ALL-diagnosis
- - -
Normal 2 (2) - - -
Decreased (<LNL) 110
(98)
5.5 (2.2–10.8) 7.4 (3.4–13.4) 17.3 (10.9–24.9)
BMI at time of ALL-
diagnosis
0.83 - 0.51
Lean 105
(83)
4.8 (1.8–10.1) 8.1 (2.8–14.7) 17.4(10.8–25.3)
Overweight 17 (13) 5.9 (3.4–24.3) - 17.7(4.1–39.1)
Obese 5 (4) - - 40.0 (3.1–78.6)
Lipids at time of ALL-diagnosis are available for 112 of the 127 patients. P-values are from Gray’s test. Abbreviations:
UNL, upper normal limit; LNL, lower normal limit; CI, confidence interval; LDL, low density lipoprotein; HDL, high
density lipoprotein; BMI, body mass index.
https://doi.org/10.1371/journal.pone.0231209.t002
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is likewise presented in cancer patients with cancer-associated cachexia[43]. However, only
scarce literature exists on this complex multi organ syndrome in children with ALL. We dem-
onstrated that 99% of the children had dyslipidemia at time of ALL-diagnosis, with abnormali-
ties in at least one type of lipids, highly dominated by decreased HDL levels and
hypertriglyceridemia and to less extent by altered TC and LDL levels. This is compatible with
previous findings from smaller ALL cohorts[25–28] possibly caused by the cancer-induced
catabolism[44]. The catabolism changes substrate supply priorities and stimulated adipose tis-
sue lipolysis in peripheral and visceral adipose storages, as well as a decreased fatty acid oxida-
tion. The increased release of free fatty acids instigate elevated hepatic production of TG and
secretion of very low density lipoprotein (VLDL)[10,44]. Furthermore, catabolism leads to
decreased levels and compositional changes of plasma LDL and HDL[44].
Overweight/obesity at time of ALL-diagnosis was associated to a poorer risk group stratifi-
cation in our study indicating a poorer treatment outcome which previously have been shown
by other studies[30,31]. Both interpatient variation of pharmacokinetics (over- and under-
treatment) as well as protective mechanisms in adipocytes have been suggested to explain a
worse therapy outcome in obese patients with ALL[30,45,46]. Furthermore, it has been dis-
cussed if obesity takes part in the’ leukemogenesis’ in adults, though it was not supported by
our results[33,47,48].
Likewise, hypercholesterolemia at time of ALL-diagnosis was associated to a worse risk
group stratification probably explained by immunophenotype since five of six of the patients
with hypercholesterolemia had T-cell ALL and will, according to the protocol, receive IR or
HR therapy. MRD measures did not support the findings possibly due to lack of power and
available MRD measures for HR patients. The lipid levels at diagnosis have not previously
been associated to treatment response. However, an association to tumor burden at diagnosis
has been indicated[26,27]. Also, differences in the leukomogenesis of T-ALL, compared to
B-ALL, might be a part of the association with hypercholesterolemia, but this need to be fur-
ther determined. We demonstrated a non-significant association between hypercholesterol-
emia at diagnosis and WBC>50x109/L as well as an association with risk of mediastinal mass,
suggesting an association between increased TC and higher tumor burden[43]. Hypercholes-
terolemia was strongly associated to immunophenotype, which suggests that T-cell leukemia
induces a different host-response, with increased levels of TC, than B-cell leukemia. However,
these results should be interpreted with care due to low numbers in the group. Furthermore,
TC was not associated to any of the measured liver numbers. No literature is available on this
topic but needs further research.
The sampling frequency and levels of on-therapy TG and TC varied considerably between
patients throughout the first year of therapy, and sampling frequency was typically higher in
periods with high levels, making it difficult to classify a patient as having high or low levels.
We hypothesized that increased lipid levels at time of ALL-diagnosis could predict on-therapy
lipid levels; however, our data did not support this. In fact, patients with elevated TG levels at
time of ALL-diagnosis had lower levels compared to those with normal or decreased levels at
time of ALL-diagnosis. This probably reflects two different mechanisms for increased TG and
TC levels at time of ALL-diagnosis and during asparaginase/dexamethasone therapy. On-ther-
apy lipid levels are known to be related to the intense therapy with glucocorticoids and aspara-
ginase[2,11,49,50], supported by the findings in the present study with the highest levels of TG
and TC during therapy with both asparaginase and dexamethasone. The wide variation in TG
and TC levels during therapy for the individual patient points to studies using systematic mea-
surements in defined time/therapy intervals to obtain a better understanding of the lipid
response during therapy, could be useful to further understand the fluctuations and relation-
ship to toxicities. Glucocorticoids are known to have anabolic side effects in children with ALL
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and cause weight gain[51]. The combination of anabolism and decreased physical activity will
lead to metabolic dysfunction (including obesity, (pre-)diabetes and cardiovascular disease) in
children with ALL both during and after treatment[52,53].
Thromboembolism in patients with ALL are usually related to complications with central
venous lines[14]. However, our age-adjusted analyses suggests an increased incidence of
thromboembolism for both hypo- and hypercholesterolemia at time of ALL-diagnosis, sup-
porting possible changes in the vascular wall exists at time of ALL-diagnosis[44] and may per-
sist during therapy. Although, central venous line and circulating factors or other pro-
thrombotic factors may also impact the risk of thromboembolism. Unfortunately, we did not
measure VLDL levels in this study, which hypothetically would track with the TG levels[44].
Furthermore, our results are in line with a large randomized controlled trial showing an asso-
ciation between the formation of blood cloths and cholesterol levels, and could indicate a need
for statin therapy, or other lipid lowering therapy, for patients being at high risk of thrombo-
embolism without having hyperlipidemia[54]. Rank et al. have shown an association between
risk of thromboembolism and immunophenotype as well as mediastinal mass[13] which sup-
port our finding on hypercholesterolemia at time of ALL-diagnosis being associated with all
three variables. The exact mechanism behind the association between hypocholesterolemia
and risk of thromboembolism needs further investigation.
The lipid levels at time of ALL-diagnosis were not associated to osteonecrosis. However, an
association between osteonecrosis and on-therapy lipid levels were previously demonstrated
by our group in a larger cohort [17]. However, this could support the notion of different causes
and implications of elevated TG levels at diagnosis versus during treatment or reflect the low
number of patients with ON in the present study. No association between the lipid levels at
diagnosis and pancreatitis were shown. Risk of pancreatitis may primarily be caused by the
intense asparaginase therapy[55], possibly by asparaginase-induced hypertriglyceridemia;
although, this remains to be demonstrated in children with ALL.
This study cohort was treated according to the same protocol and population based, repre-
senting all patients below 18 years of age, diagnosed with ALL in the eastern part of Denmark
since 2008 (approximately 50% of the national cohort). However, the study is limited by the
size of the cohort, its retrospective design and lack of systematic lipid measures during
therapy.
Cardio-metabolic conditions are emerging concerns in children during and after ALL ther-
apy. To clarify this major issue a better understanding of the interaction between the dyslipi-
demic host-response, prior to and during ALL therapy, and the ALL is needed.
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